BRIDGE PHARMACEUTICALS
DEDICATES BEIJING LAB
Newsom sees lab as keeping
San Francisco competitive in life sciences

November 28, 2005

SAN FRANCISCO -- (BUSINESS WIRE) -- Bridge Pharmaceuticals yesterday dedicated its recently completed Bridge Zhongguancun Preclinical Drug Development Laboratory I.

In attendance at the ceremony were: San Francisco Mayor Gavin Newsom; Deputy Mayor Beijing Municipal Office Hao Lu; Beijing Deputy Mayor Bo-Yuan Fan; US Embassy Senior Commercial Officer Craig Allen; Former Beijing Deputy Mayor Zhao-Guang Hu; Director of Beijing Municipal Industrial Development Bureau Lian-Yuan Cheng; Director of Beijing Municipal Science Technology Office Hai Feng; and Former San Francisco Mayor Frank Jordon.

This 7,800 square meter facility puts Bridge at the forefront of preclinical outsourcing to China and will be the first and only US level GLP and AAALAC designed facility in China. The Zhongguancun facility will house primates, rodents, canines, rabbits. Services will include: FDA compliant GLP toxicology, pharmacology, predictive PK/ADMET, safety pharmacology, formulation and other services. Through its Vital Bridge joint venture, Bridge has expert local partners in China that provide animal supplies from the largest and only US-franchised (Charles River and Marshall Farms) quality animal breeding facilities in China.

For Bridge, the opening of this facility marks the next phase in outsourcing preclinical drug development to Asia. By controlling its own facility in China, Bridge will have the capacity and expertise to provide FDA compliant preclinical drug development services to pharmaceutical and biotech companies throughout the world. This new facility positions Bridge as the leading preclinical CRO in China targeting US and EU biopharmaceutical companies.

"The San Francisco Bay Area is the birthplace of biotech and has remained the worldwide leader in life sciences innovation. Escalation of the price of drugs, as evidenced by California's recent ballot initiative, is an increasing hardship and concern," said San Francisco Mayor Gavin Newsom.

"By combining the technical resources and innovation of both the San Francisco Bay Area and Beijing's life sciences community, this state-of-the-art facility represents the next wave of global cooperation and evolution of life sciences development. Bridge, and companies like Bridge, will allow San Francisco to remain competitive in the life sciences, and cost effectively develop more drugs, for smaller markets, in the new era of personalized molecular medicine. We are pleased to see that a Bay Area company, Bridge Pharmaceuticals, is taking the lead in this exciting global evolution of the very best of the east and west."

Founded in 2004, Bridge Pharmaceuticals, Inc. was spun-out of SRI International (formerly Stanford Research Institute) to develop preclinical service and drug development capabilities through leverage of the Asian market. To date, Bridge has been subcontracting work through laboratories in China and Taiwan (Beijing, Shanghai, Chengdu, Taipei and elsewhere).

Bridge is the first company to successfully use all China preclinical and CMC data for successful filing of IND's with the US FDA and did so twice this year.

"Two years ago, we asked a simple question -- why can't one perform FDA compliant drug development in China for US clients at a fraction of the normal price?" CEO and President, Glenn Rice, Ph.D. said.

"China has the world's leading primate animal supply, highly qualified technical staff, good English language skills and excellent worker productivity, in addition to significant cost savings. Bridge builds on China's strengths by adding: SOP sourcing from the US, world class facilities in the leading life sciences park in China, FDA compliance, AAALAC level animal welfare, real time data monitoring, combined with a US headquartered company that envisions flexible partnerships.

"Of course doing business in China takes a lot of local know how, experienced investment strategy and government support. We are combining the best of east and west and we are confident it is going to revolutionize preclinical drug development worldwide. We are indebted to our investors, particularly Peter Liu, Chairman of the WI Harper Group who has guided our business from day one in China."

About Bridge Pharmaceuticals

Bridge Pharmaceuticals is a US-headquartered, SRI International spin-off company focused on providing cost effective, FDA compliant drug development services in Asia for US, EU and Asian based clients. Bridge has also formed BridgeNet, an unprecedented network of pre-screened chemical and manufacturing service providers in China and Taiwan, which provides western clients with a single point of contact to access highly qualified and cost effective drug development services in Asia. Bridge provides complete end-to-end drug development expertise including US IND submissions. Bridge focuses its development work in Taiwan and China.

For more information, visit www.BridgePharmaceuticals.com or call 650-859-3853.

####